Global Markets Direct’s, Epilepsy – Pipeline Review, H2 2016′, provides an overview of the Epilepsy pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Epilepsy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Epilepsy and features dormant and discontinued projects.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Complete report on Epilepsy – Pipeline Review, H2 2016′ addition with 110 market data tables and 16 figures, spread across 421 pages is http://www.rnrmarketresearch.com/epilepsy-pipeline-review-h2-2016-market-report.html
This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis
Adamas Pharmaceuticals, Inc , Advicenne, Aeolus Pharmaceuticals, Inc Aequus Pharmaceuticals Inc Aestus Therapeutics, Inc Alexza Pharmaceuticals, Inc Anavex Life Sciences Corp Asklepios BioPharmaceutical, Inc Astellas Pharma Inc Bial – Portela & Ca, S.A BioCrea GmbH Biogen Inc Bionomics Limited, Biovista Inc Biscayne Pharmaceuticals, Inc Catalyst Pharmaceuticals, Inc D-Pharm Ltd Eisai Co., Ltd Glialogix, Inc Grifols, S.A GW Pharmaceuticals Plc, H. Lundbeck A/S, Hyundai Pharmaceutical Co., Ltd INSYS Therapeutics, Inc INVENT Pharmaceuticals, Inc Iproteos S.L Johnson & Johnson Knopp Biosciences LLC, Lead Discovery Center GmbH, Lipicard Technologies Limited, Lotus Pharmaceutical Co., Ltd Marathon Pharmaceuticals, LLC,
Marinus Pharmaceuticals, Inc ,Mitochon Pharmaceuticals, Inc ,Neurelis, Inc ,Neurocrine Biosciences, IncNeuron Biopharma SA,Novartis AG,OPKO Health, Inc ,Ovid Therapeutics Inc ,Pfizer Inc ,PharmatrophiX, Inc,Promius Pharma, LLC,PTC Therapeutics, Inc ,Retrophin Inc ,Sage Therapeutics, IncSaniona AB,SciFluor Life Sciences, LLC,Shire Plc,SK Biopharmaceuticals Co., Ltd,Suda Ltd,Sumitomo Dainippon Pharma Co., Ltd ,Takeda Pharmaceutical Company Limited,Trillium Therapeutics Inc ,Turing Pharmaceuticals AG ,UCB S.A ,Ultragenyx Pharmaceutical Inc ,Upsher-Smith Laboratories, Inc ,Vichem Chemie Research LtdVistaGen Therapeutics , IncVitality Biopharma Inc, Xenon Pharmaceuticals IncXERIS Pharmaceuticals, IncZogenix, IncZynerba Pharmaceuticals, Inc
Inquire before buying for this report :http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=692215 (This is a premium report price at US$2000 for a single user PDF license).